Alnylam Pharmaceuticals (ALNY) Current Assets (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Current Assets came in at $4.6 billion in Q2 2026, up 26.8% YoY from $3.6 billion in Q2 2025, and up 9.5% on a QoQ basis from $4.2 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Current Assets (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Current Assets data on file, last reported at $4.6 billion in Q2 2026.
- Quarterly Current Assets rose 26.8% year-over-year to $4.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.6 billion (up 26.8% YoY) and the FY2025 annual result came in at $4.1 billion, up 22.92% from the prior year.
- Current Assets advanced to $4.6 billion in Q2 2026, from $4.2 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $4.6 billion in Q2 2026 to a low of $2.5 billion in Q2 2022.
- A 5-year average of $3.2 billion and a median of $3.1 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets decreased 9.3% — and 2026, when it rose 29.1%.
- Tracing ALNY's Current Assets over 5 years: stood at $2.7 billion in 2022, then climbed by 10.79% to $3.0 billion in 2023, then rose by 10.48% to $3.3 billion in 2024, then advanced by 22.92% to $4.1 billion in 2025, then grew by 14.06% to $4.6 billion in 2026.
- The last three Current Assets figures came in at $4.6 billion (Q2 2026), $4.2 billion (Q1 2026), and $4.1 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.62 Bn |
| Mar 31, 2026 | 4.22 Bn |
| Dec 31, 2025 | 4.05 Bn |
| Sep 30, 2025 | 3.95 Bn |
| Jun 30, 2025 | 3.64 Bn |
| Mar 31, 2025 | 3.27 Bn |
| Dec 31, 2024 | 3.30 Bn |
| Sep 30, 2024 | 3.36 Bn |
| Jun 30, 2024 | 3.17 Bn |
| Mar 31, 2024 | 2.99 Bn |
| Dec 31, 2023 | 2.98 Bn |
| Sep 30, 2023 | 2.99 Bn |
| Jun 30, 2023 | 2.52 Bn |
| Mar 31, 2023 | 2.54 Bn |
| Dec 31, 2022 | 2.69 Bn |
| Sep 30, 2022 | 2.69 Bn |
| Jun 30, 2022 | 2.47 Bn |
| Mar 31, 2022 | 2.59 Bn |
| Dec 31, 2021 | 2.81 Bn |
| Sep 30, 2021 | 2.68 Bn |